Cardiovascular Drugs Practice Questions

Q: All of the following statements about beta blockers are true EXCEPT?

Atenolol is safe in renal failure.. ### Explanation **1. Why Option D is the Correct Answer (The False Statement):** Atenolol is a **highly hydrophilic (water-soluble)** beta-blocker. Unlike lipophilic drugs (like Propranolol) which are metabolized by the liver, Atenolol is primarily excreted **unchanged by the kidneys**. Therefore, in patients with renal failure, the drug accumulates, leading to toxicity (profound bradycardia and hypotension). It requires significant dose adjustment or avoidance in renal impairment. **2. Analysis of Other Options:** * **Option A (True):** Nebivolol is a third-generation, **highly cardioselective** $\beta_1$ blocker. It also possesses unique vasodilatory properties mediated by the release of Nitric Oxide (NO) from the endothelium. * **Option B (True):** Cardioselective beta-blockers (e.g., Metoprolol, Atenolol, Bisoprolol) preferentially block $\beta_1$ receptors. While they are "relatively" safe in mild-to-moderate asthma because they avoid $\beta_2$ blockade (which causes bronchospasm), they should still be used with extreme caution as selectivity is lost at higher doses. * **Option C (True):** In **acute** decompensated heart failure, beta-blockers are contraindicated because their negative inotropic effect can further worsen cardiac output. However, they are a cornerstone of therapy in **chronic** stable heart failure (specifically Metoprolol succinate, Bisoprolol, and Carvedilol). **3. NEET-PG High-Yield Pearls:** * **Lipophilic Beta Blockers:** Propranolol, Metoprolol. (Undergo extensive first-pass metabolism; cross the Blood-Brain Barrier). * **Hydrophilic Beta Blockers:** Atenolol, Sotalol, Nadolol. (Excreted by kidneys; longer half-lives). * **Shortest Acting:** Esmolol (metabolized by RBC esterases; $t_{1/2} \approx 9$ mins). * **Longest Acting:** Nadolol. * **Beta Blockers with ISA (Intrinsic Sympathomimetic Activity):** Pindolol, Acebutolol (preferred in patients with resting bradycardia).

Q: Which drug possesses beta-adrenergic blocking, antioxidant, calcium channel blocking, and alpha-1 antagonist activities?

Carvedilol. **Explanation:** **Carvedilol** is a unique, non-selective third-generation beta-blocker. Its multifaceted pharmacological profile makes it the correct answer: * **Beta-Blocking:** It blocks both $\beta_1$ and $\beta_2$ receptors. * **Alpha-1 Antagonism:** It provides peripheral vasodilation by blocking $\alpha_1$ receptors, which reduces afterload. * **Antioxidant Activity:** It possesses carbazole rings that scavenge free radicals, preventing lipid peroxidation and protecting the myocardium from oxidative stress. * **Calcium Channel Blocking:** At higher concentrations, it exhibits membrane-stabilizing activity and weak L-type calcium channel blockade. **Analysis of Incorrect Options:** * **A. Esmolol:** An ultra-short-acting, cardioselective ($\beta_1$) blocker. It lacks alpha-blocking or antioxidant properties and is primarily used for acute arrhythmia or intraoperative hypertension. * **C. Nebivolol:** A highly selective $\beta_1$ blocker. While it causes vasodilation, it does so via **Nitric Oxide (NO) release**, not $\alpha_1$ blockade. It does not have significant calcium channel blocking activity. * **D. Levobunolol:** A non-selective beta-blocker used topically in the eye for glaucoma. It lacks the ancillary vasodilator and antioxidant properties of carvedilol. **High-Yield Clinical Pearls for NEET-PG:** * **Heart Failure:** Carvedilol is a "gold standard" beta-blocker (along with Metoprolol succinate and Bisoprolol) proven to reduce mortality in Chronic Heart Failure (CHF). * **Lipid Neutrality:** Unlike first-generation beta-blockers, carvedilol does not adversely affect lipid profiles or insulin sensitivity due to its $\alpha_1$ blocking effect. * **Metabolism:** It is highly lipophilic and undergoes extensive hepatic metabolism.

Q: A 34-year-old lady on antihypertensives presented with certain features. Which of the following drugs is likely responsible for this condition?

Minoxidil. ***Minoxidil*** - **Minoxidil** is a potent vasodilator that commonly causes **hypertrichosis** (excessive hair growth), particularly noticeable in women as unwanted facial and body hair. - This **cosmetic side effect** is dose-dependent and reversible upon discontinuation, making it a characteristic adverse effect of minoxidil therapy. *Enalapril* - **ACE inhibitors** like enalapril typically cause a **dry cough** (10-15% of patients) due to increased bradykinin levels. - Other common side effects include **hyperkalemia** and **angioedema**, but not hypertrichosis. *Trimetazidine* - This **anti-anginal agent** works by optimizing cardiac metabolism and rarely causes significant cosmetic side effects. - Main adverse effects include **gastrointestinal disturbances** and occasional **movement disorders**, not hair growth changes. *Methyldopa* - **Methyldopa** commonly causes **sedation**, **depression**, and **positive Coombs test** leading to hemolytic anemia. - Other notable side effects include **hepatotoxicity** and **drug-induced lupus**, but hypertrichosis is not associated with this medication.

Q: Which of the following drugs does NOT increase nitric oxide levels?

Fenoldopam. **Explanation:** The correct answer is **Fenoldopam** because its mechanism of action is entirely independent of the Nitric Oxide (NO) pathway. **1. Why Fenoldopam is the correct answer:** Fenoldopam is a selective **Dopamine $D_1$ receptor agonist**. It causes vasodilation by increasing intracellular cyclic AMP (cAMP) in vascular smooth muscle cells. It is unique because it causes rapid vasodilation while simultaneously increasing renal perfusion and promoting natriuresis (sodium excretion). It does not involve the release or stimulation of Nitric Oxide. **2. Why the other options are incorrect:** * **Glycerine trinitrate (GTN):** An organic nitrate that undergoes enzymatic conversion (via mitochondrial aldehyde dehydrogenase) to release **Nitric Oxide (NO)**, which activates guanylyl cyclase to increase cGMP. * **Sodium Nitroprusside (SNP):** A direct-acting vasodilator that non-enzymatically releases **Nitric Oxide** into the bloodstream. It acts on both arterioles and venules. * **Hydralazine:** Though its mechanism is complex, it is known to stimulate the release of **Nitric Oxide** from the vascular endothelium, leading to arteriolar vasodilation. **3. NEET-PG Clinical Pearls:** * **Fenoldopam** is the drug of choice for hypertensive emergencies in patients with **renal insufficiency** due to its renal-sparing effects. * **Sodium Nitroprusside** can lead to **Cyanide/Thiocyanate toxicity** with prolonged use; the antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Nitrates** primarily cause venodilation (reducing preload), whereas **Hydralazine** primarily causes arteriolar dilation (reducing afterload). * **Tachyphylaxis** (tolerance) is a common issue with chronic Nitrate use, requiring a "nitrate-free interval."

Q: Which of the following antihypertensive medications can cause impotence?

Propranolol, Atenolol, Nifedipine. **Explanation:** The correct answer is **B (Propranolol, Atenolol, Nifedipine)**. Sexual dysfunction, specifically erectile dysfunction (impotence), is a well-documented side effect of several classes of antihypertensive drugs. **1. Why Option B is Correct:** * **Beta-Blockers (Propranolol, Atenolol):** These are the most common culprits. They cause impotence through multiple mechanisms: reducing central sympathetic outflow, causing peripheral vasoconstriction (via $\beta_2$ blockade), and potentially lowering testosterone levels. Non-selective blockers (Propranolol) generally have a higher incidence than cardioselective ones (Atenolol), but both are implicated. * **Calcium Channel Blockers (Nifedipine):** While less common than with beta-blockers or diuretics, dihydropyridine CCBs like Nifedipine have been associated with impotence in clinical practice and trials. **2. Analysis of Incorrect Options:** * **ACE Inhibitors (Options A & C):** These are considered "sexually neutral" or even beneficial. By blocking Angiotensin II (a vasoconstrictor), they may improve penile blood flow. Therefore, options containing ACE inhibitors are incorrect. * **Option D:** While both drugs cause impotence, this option is less comprehensive than Option B, which includes Atenolol—another major causative agent. **3. NEET-PG High-Yield Pearls:** * **Most Common Offenders:** Thiazide diuretics (e.g., Chlorthalidone) and Beta-blockers are the two classes most frequently associated with erectile dysfunction. * **The "Safe" Drugs:** ACE inhibitors, ARBs (especially **Losartan**, which may improve sexual function), and Nebivolol (a $\beta_1$ blocker that increases Nitric Oxide) are preferred in patients concerned about sexual side effects. * **Centrally Acting Drugs:** Clonidine and Methyldopa also have high rates of causing impotence due to their effect on the CNS.

Q: What is the primary route of administration for glyceryl trinitrate for acute angina relief?

Sublingual. Explanation: 1. Why Sublingual is Correct: Glyceryl Trinitrate (GTN) is the drug of choice for the immediate relief of an acute anginal attack. The sublingual route is preferred because the oral mucosa is highly vascular, allowing the drug to bypass the portal circulation [1]. This avoids the extensive first-pass metabolism (nearly 90%) that occurs in the liver [1]. It ensures a rapid onset of action (1–3 minutes), providing quick vasodilation of coronary arteries and peripheral veins, which reduces cardiac preload and myocardial oxygen demand [2]. 2. Why Other Options are Incorrect: * Oral: GTN has very low bioavailability when swallowed due to significant hepatic first-pass metabolism [1]. While sustained-release oral nitrates exist for prophylaxis, they are ineffective for acute relief. * Submucosal: While similar to sublingual, it is not the standard clinical practice for GTN administration. Sublingual placement (under the tongue) offers the most rapid absorption surface. * Rectal: Although this route bypasses some first-pass metabolism, it is clinically impractical, socially unacceptable for this indication, and has a much slower absorption rate compared to the sublingual route. 3. High-Yield Clinical Pearls for NEET-PG: * Storage: GTN is volatile and light-sensitive; it must be stored in dark-colored glass bottles with tight metal caps. * Patient Counseling: Patients should be told to sit down before taking the dose to avoid orthostatic hypotension and syncope. * Tolerance: To prevent "nitrate tolerance," a nitrate-free interval of 8–12 hours (usually at night) is required [2]. * Contraindication: Never co-administer with Sildenafil (PDE-5 inhibitors) as it can lead to life-threatening hypotension.

Q: Ivabradine is used in the treatment of which condition?

Angina. **Explanation:** **Ivabradine** is a unique cardiovascular drug that acts as a selective and specific inhibitor of the **cardiac pacemaker $I_f$ current** (the "funny" current) in the sinoatrial (SA) node. **1. Why Angina is Correct:** By inhibiting the $I_f$ current, Ivabradine slows the firing rate of the SA node, leading to a **dose-dependent reduction in heart rate**. Unlike beta-blockers, it reduces heart rate without affecting myocardial contractility (inotropy) or ventricular repolarization. In chronic stable angina, this reduction in heart rate decreases myocardial oxygen demand and increases diastolic perfusion time, effectively relieving ischemic symptoms. It is particularly useful in patients who have contraindications to beta-blockers (e.g., asthma). **2. Why Other Options are Incorrect:** * **Ventricular/Atrial Arrhythmias:** Ivabradine is not an anti-arrhythmic drug. It does not affect sodium, potassium, or calcium channels involved in tachyarrhythmias. In fact, it is ineffective in atrial fibrillation because the heart rate is not controlled by the SA node in that condition. * **Hypertension:** Ivabradine has no effect on peripheral vascular resistance or systemic blood pressure; therefore, it plays no role in treating hypertension. **3. High-Yield NEET-PG Pearls:** * **Mechanism:** Selective $I_f$ current inhibitor in the SA node. * **Clinical Use:** Chronic stable angina and Chronic Heart Failure (NYHA Class II-IV) with LVEF ≤ 35% in patients in sinus rhythm with a resting HR ≥ 70 bpm. * **Side Effects:** The most characteristic side effect is **luminous phenomena (phosphenes)**—enhanced brightness in limited areas of the visual field—caused by the inhibition of $I_h$ currents in the retina. * **Requirement:** The patient **must be in sinus rhythm** for the drug to be effective.

Q: What is the half-life of digoxin?

40 hours. **Explanation:** **Digoxin** is a cardiac glycoside used in the management of heart failure and atrial fibrillation. Its pharmacokinetic profile is a high-yield topic for NEET-PG. 1. **Why 40 hours is correct:** The average elimination half-life ($t_{1/2}$) of digoxin in a healthy individual with normal renal function is approximately **36 to 40 hours**. Because of this relatively long half-life, it takes about 5 to 7 days (4–5 half-lives) to reach a steady-state plasma concentration if a constant daily maintenance dose is started without a loading dose. 2. **Analysis of Incorrect Options:** * **24 hours (A):** This is too short for digoxin. However, it is closer to the half-life of *Digitoxin* in species with rapid metabolism, though in humans, Digitoxin lasts much longer (5–7 days). * **48 hours (C) & 60 hours (D):** While the half-life of digoxin can extend to 48–60 hours or more in patients with **renal impairment**, these are not the standard physiological values for a healthy adult. **High-Yield Clinical Pearls for NEET-PG:** * **Excretion:** Digoxin is primarily excreted **unchanged by the kidneys**. Therefore, the dose must be strictly reduced in patients with renal failure to prevent toxicity. * **Volume of Distribution:** It has a very high $V_d$ (approx. 6–7 L/kg) because it binds extensively to skeletal muscle (Na+/K+ ATPase). It is **not** removed by dialysis. * **Therapeutic Window:** It has a narrow therapeutic index (0.5–2 ng/mL). * **Toxicity Factors:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. The most common initial symptom of toxicity is anorexia/nausea, while the most characteristic arrhythmia is **Non-paroxysmal AV junctional tachycardia** and the most common is **PVCs**.

Question 1

All of the following statements about beta blockers are true EXCEPT?

Accepted Answer

Atenolol is safe in renal failure.

Answer

Nebivolol is a cardioselective beta blocker.

Answer

Cardioselective beta blockers are relatively safe in asthma.

Answer

Beta blockers are contraindicated in acute congestive heart failure.

Question 2

Which drug causes a decrease in the late sodium current?

Accepted Answer

Ranolazine

Answer

Nicorandil

Answer

Trimetazidine

Answer

Molsidomine

Question 3

Which drug possesses beta-adrenergic blocking, antioxidant, calcium channel blocking, and alpha-1 antagonist activities?

Accepted Answer

Carvedilol

Answer

Esmolol

Answer

Nebivolol

Answer

Levobunolol

Question 4

A 34-year-old lady on antihypertensives presented with certain features. Which of the following drugs is likely responsible for this condition?

Accepted Answer

Minoxidil

Answer

Enalapril

Answer

Trimetazidine

Answer

Methyldopa

Question 5

Which of the following drugs are known to cause fetal renal anomalies?

Accepted Answer

Enalapril

Answer

Frusemide

Answer

Angiotensin receptor blocker

Answer

Amlodipine

Question 6

Which of the following drugs does NOT increase nitric oxide levels?

Accepted Answer

Fenoldopam

Answer

Glycerine trinitrate

Answer

Hydralazine

Answer

Sodium Nitroprusside

Question 7

Which of the following antihypertensive medications can cause impotence?

Accepted Answer

Propranolol, Atenolol, Nifedipine

Answer

ACE inhibitors, Propranolol, Atenolol

Answer

ACE inhibitors, Atenolol

Answer

Propranolol, Nifedipine

Question 8

What is the primary route of administration for glyceryl trinitrate for acute angina relief?

Accepted Answer

Sublingual

Answer

Oral

Answer

Submucosal

Answer

Rectal

Question 9

Ivabradine is used in the treatment of which condition?

Accepted Answer

Angina

Answer

Ventricular arrhythmia

Answer

Atrial arrhythmia

Answer

Hypertension

Question 10

What is the half-life of digoxin?

Accepted Answer

40 hours

Answer

24 hours

Answer

48 hours

Answer

60 hours

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?